A novel neuregulin isoform, termed g-HRG, was cloned and characterized from the human breast cancer cell line, MDA-MB-175. As observed with other neuregulins, g-HRG, is a product of alternative mRNA splicing of the neuregulin gene. g-HRG contains the EGF-like and immunoglobulin-like domains that are commonly found in other family members, but lacks a transmembrane and cytoplasmic region. The new isoform possesses a unique N-terminal region that includes a hydrophobic domain that may function as a secretion signal. A puri®ed recombinant version of g-HRG competes for binding to soluble ErbB3-and ErbB4-IgG fusion proteins with anities similar to those observed for rHRGb1 177 ± 244 . g-HRG has a wide distribution in mesenchymal or neuronal tissues but in contrast to other neuregulins, it is not present in breast, lung, liver and small intestine. Expression of g-HRG with its cognate receptors, ErbB3 and ErbB2 suggested that the growth of the MDA-MB-175 cell line might be a result of the autocrine stimulation of a growth factor signaling pathway. Treatment of MDA-MB-175 cells with an anti-ErbB2 monoclonal antibody that interferes with the liganddependent formation of ErbB2-ErbB3 heterodimer complexes shows a strong growth inhibitory eect on this cell line. Moreover, incubation with a receptor-IgG fusion protein that neutralizes secreted g-HRG, also inhibits cell growth. These data suggest that the secretion of g-HRG by MDA-MB-175 cells leads to the formation of a constitutively active receptor complex and stimulates the growth of these cells in an autocrine manner.
Introduction
The ErbB family of receptor tyrosine kinases are important mediators of cell growth, dierentiation and survival. The receptor family is composed of four distinct members including epidermal growth factor receptor (EGFR or ErbB1), ErbB2 (neu or HER2), ErbB3 (HER3) and ErbB4 (tyro2 or HER4). Within a given tissue, these receptors are rarely if ever expressed alone, but are found in various combinations. Heterodimerization of ErbB receptors (Earp et al., 1995) appears to increase the diversity of cellular responses to a variety of proteins that serve as ligands for these receptors (Pinkas-Kramarski et al., 1996; Riese II et al., 1995) . The prototypical member of this family, EGFR, is activated by six dierent gene products including: EGF, TGFa, amphiregulin, heparin-binding EGF, betacellulin and epiregulin (Groenen et al., 1994; Toyoda et al., 1995) . In contrast, a family of proteins, collectively known as neuregulins, are ligands for the two more recently discovered receptors, ErbB3 and ErbB4 (Plowman et al., 1993) . Recently, two additional neuregulin genes have been identi®ed (Burden and Yarden, 1997) . Neuregulin-2 appears to be a ligand for either ErbB3 or ErbB4 (Chang, 1997; Carraway III, 1997) , whereas neuregulin-3 may be speci®c for ErbB4 (Zhang et al., 1997) . ErbB2 is activated as a result of neuregulin binding to ErbB3 or ErbB4. Furthermore, blocking the association of ErbB2 with ErbB3 or ErbB4 inhibits neuregulinmediated signaling (Graus-Porta et al., 1995 , 1997 Karunagaran et al., 1996; Lewis et al., 1996) . Consequently, ErbB2 is an essential component of a neuregulin-receptor complex, although in a strict sense it is an orphan receptor in that no ligand has been characterized at the molecular level that interacts with ErbB2 alone. EGFR (Modjtahedi and Dean, 1994) or ErbB2 (Graus-Porta et al., 1995; Hynes, 1993; Slamon et al., 1987) overexpression is a molecular alteration that frequently occurs in a number of human cancers and in many cases has been correlated with poor clinical outcome.
Multiple neuregulin isoforms are generated from alternative splicing of mRNA transcripts derived from a single gene (Marchionni et al., 1993) . Major motifs found in the resulting proteins include: kringle, immunoglobulin-like, N-and O-linked glycosylation (spacer) region, EGF-like, juxtamembrane, transmembrane and cytoplasmic domains. The roles that these motifs play in mediating neuregulin biological activities are unclear, since recombinant (Holmes et al., 1992) and synthetic versions (Barbacci et al., 1995) of the EGF-like domain are sucient for receptor activation and are active in a number of biological assays. The domains outside the EGF region may function to regulate neuregulins' pleiotrophic biological activities. For example, intracellular or membrane processing of pro-HRG isoforms is critical to generate soluble forms of these factors that may in turn mediate mesenchymeepithelial interactions in tissues such as breast (Burgess et al., 1995) . Alternatively, the ability of the N-terminal region of neuregulin to interact with proteoglycans may sequester the proteins on the extracellular matrix and limit their ability to freely diuse and therefore function to localize their biological activity. For example, deposition of neuregulins on extracellular matrix occurs at the neuronal-Schwann cell interface (Morrissey et al., 1995) and at neuromuscular junctions (Loeb and Fischbach, 1995) .
In this paper we describe the cloning of a novel neuregulin isoform, which we term g-HRG. g-HRG contains a unique N-terminal region which appears to mediate its cellular secretion. Structurally, g-HRG has similarities to neuronal neuregulins in that it contains a b3 EGF-like domain and it does not contain a transmembrane region. g-HRG was cloned from the human breast tumor cell line MDA-MB-175, which also expresses ErbB3 and ErbB2. Using a soluble receptor fusion protein and monoclonal antibody that disrupt the association of ErbB3 with ErbB2, we demonstrate that g-HRG is directly involved in Figure 1 cDNA and deduced amino acid sequence of g-HRG. The hydrophobic region is underlined. The EGF-like domain is shaded, cysteine residues in the EGF-like domain are circled. Potential N-glycosylation sites are designated by (.) autocrine growth of MDA-MB-175 cells. These studies suggest that autocrine stimulation of neuregulin receptors may play an important role in human tumor growth.
Results

Isolation and sequence analysis of g-HRG
Previous reports have suggested that the breast tumor cell line, MDA-MB-175, expresses a novel neuregulin transcript (Alimandi et al., 1995; Park et al., 1993) . To characterize the neuregulin transcript in this cell line, a lgt 10 cDNA library was prepared with mRNA from MDA-MB-175 cells. The library was screened with a cDNA probe corresponding to the EGF-like domain of HRGb3 and various clones were identi®ed. Multiple hybridizing clones were isolated and sequenced. We termed these unique clones, g-HRG. The cDNA and the deduced amino acid sequences of g-HRG are shown in Figure 1 . The single open reading frame of 2303 bp starts with an ATG codon at nt 334. The start codon lies in a nucleotide sequence context, that is a potential translation initiation site (Kozak, 1987) . Several termination codons are located upstream of the initiation codon. The stop codon, TAG, at nt 2637 is followed by a 3' noncoding sequence, identical to other HRG isoform sequences and includes a polyadenylation signal followed by an A-rich region. The open reading frame encodes a protein of 768 amino acid residues with a predicted molecular mass of 84.2 kDa.
Structural analysis of g-HRG g-HRG contains an EGF-like domain which is identical to that contained in HRGb3, glial growth factor (GGF) and sensory and motor neuron derived factor (SMDF) (Figure 2 ). The amino acid sequence of g-HRG ends in the juxtamembrane domain and it lacks a transmembrane region and a cytoplasmic domain. As observed with HRGa and HRGb, the spacer domain and the Ig-like domain are also present. The spacer domain contains potential N-and O-linked glycosylation sites. The N-terminal region is unique and distinct from all other neuregulins. The ®rst 33 amino acids which are found in HRGa and HRGb are absent. Instead g-HRG possesses a 560 amino acid sequence, which shows no similarity to any known DNA or protein sequences. A feature in common with other neuregulin isoforms is that g-HRG lacks an N-terminal signal sequence. However, within the unique Nterminal region a 22 amino acid stretch of hydrophobic residues is present which may function as an internal signal sequence and mediate secretion across the cell membrane.
Identi®cation of g-HRG transcripts in breast tumor cell lines and human tissues
To compare the heregulin transcripts in MDA-MB-175, MDA-MB-231 cell lines and mammary gland tissue, a Northern blot analysis was performed on poly(A) + RNA. In agreement with previous studies, Northern blot analysis performed with a 32 P-labeled cDNA probe corresponding to the EGF-like domain of HRGb3 detected a major transcript of 1.8 kb and minor transcripts of 2.5 and 6.6 kb, with RNA obtained from the breast tumor cell line MDA-MB-231 ( Figure 3a , lane 1) (Holmes et al., 1992) . The breast cancer cell lines MCF-7, MDA-MB-453, MDA-MB-468, BT-474 and SK-BR-3 do not express neuregulin transcripts as determined by Northern blot analysis or PCR (Park et al., 1993) . A similar transcript pattern was also observed in RNA derived from normal breast tissue (Figure 3a, lane 3) . The relative abundance of the 6.6 kb transcript was greater with RNA from normal breast tissue than from MDA-MB-231 cells. However, in MDA-MB-175 RNA only one major transcript of 3.3 kb was observed ( Figure  3a , lane 2). When a 32 P-labeled cDNA probe corresponding to the unique N-terminal sequence of g-HRG was used, no hybridization signals could be located in either MDA-MB-231 RNA or in RNA derived from human breast tissue (Figure 3b, lanes 1,  3) . Only the major 3.3 kb message could be detected in MDA-MB-175 RNA (Figure 3b , lane 2). Minor bands of lower intensities with the sizes of 1.8 kb, 5 kb and 8.5 kb were also observed. These signals were also present in autoradiograms after extensive exposure using the EGF-like domain probe (data not shown). Various human tissues were examined for the presence of g-HRG mRNA (Figure 3c ). Transcripts containing the unique N-terminal sequence were found in testis, ovary, skeletal muscle and in lower abundance in heart, brain, kidney, thymus and prostate. No transcripts could be found by Northern blot analysis in spleen, small intestine, colon, peripheral blood leukocytes, placenta, lung, liver and pancreas. As observed with other neuregulin isoforms, the size of the transcripts in We addressed the possibility that g-HRG might not be a splice variant of the neuregulin gene, but rather the result of DNA rearrangement in this breast cancer cell line. We performed Southern blot analysis of genomic DNA obtained from MDA-MB-231 and MDA-MB-175 cells. Genomic DNA from each cell line was digested with EcoRI, BamHI, HindIII, PstI, Styl ( Figure 4 ) and size fractionated on a 1% agarose gel. The blot was hybridized with a 32 P-labeled cDNA probe (nt 1690 ± 2351) of g-HRG. The 5' end of the cDNA probe was complementary to the unique Nterminal sequence. The 3' end contained a part of the commonly shared neuregulin sequence, which Marchionni et al. (1993) de®ned as exon 2. This probe was designed to span the exon/intron junction, a potential DNA rearrangement site. Figure 4 shows the band pattern of genomic DNA from MDA-MB-175 and MDA-MB-231 cells digested with the indicated restriction enzyme. In addition, to rule out the possibility of upstream rearrangement, the entire unique 5' sequence of g-HRG was used as a probe and a similar band pattern was observed in both cell lines (data not shown). These data suggest that g-HRG is not a product of DNA rearrangement, but rather a new splice variant of the neuregulin gene.
Functional activity of g-HRG
Unlike HRGa or HRGb, which were originally puri®ed from the conditioned medium of MDA-MB-231 cells, wild type g-HRG activity from MDA-MB-175 cell conditioned medium did not bind to heparin columns (data not shown) (Holmes et al., 1992) . To characterize the physical and functional properties of the protein, g-HRG was partially puri®ed from medium conditioned by MDA-MB-175 cells using reversed phased HPLC. The apparent molecular size of the puri®ed g-HRG was determined by Western blot using an ErbB2/ErbB4-IgG for detection. Full length rHRGb1, expressed in CHO cells, migrated with a molecular size of *45 kDa, whereas g-HRG secreted from MDA-MB-175 cells has a molecular size of *64 kDa ( Figure 5a ). This size is signi®cantly lower than the predicted molecular size of g-HRG, which suggests that processing of g-HRG occurred during or + RNA from mammary gland (Clontech) was size fractionated on a 0.8% formaldehyde/1% agarose gel, transferred to nylon membrane and hybridized with either (a) 32 P-labeled EGF-like domain of HRGb3 or (b) the 32 Plabeled g-HRG speci®c probe (nt 1238 ± 1868) as described iǹ Materials and methods'. Filters were washed and the autoradiographs were developed after 7 and 40 h exposure. RNA molecular weight markers were run on the gels and are indicated on the side. (c) Human multiple tissue Northern blots (Clontech) containing 2 mg poly (A) + from spleen, thymus, prostate, testis, ovary, small intestine, colon, peripheral blood leukocytes, heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas were hybridized with a speci®c g-HRG probe (nt 841 ± 1447) and autoradiograms were developed after 5 days exposure Sty I Figure 4 Southern blot analysis. Genomic DNA of MDA-MB-175 and MDA-MB-231 cells was digested with the restriction enzyme indicated and 10 mg of each digest was loaded on a 1% agarose gel. DNA was blotted and hybridized as described iǹ Materials and methods'. A BgIII-NdeI cDNA fragment of g-HRG (nt 1690 ± 2351) was radiolabeled and used for hybridization. The DNA fragments digested with PstI and StyI were run on a separate gel. Autoradiographs were developed after 9 ± 24 h exposure g-Heregulin G Schaefer et al after secretion from MDA-MB-175 cells. Additionally, a pRK7 expression vector was constructed which contained the g-HRG cDNA sequence (nt 1104 ± 3111). The human embryonic kidney cell line (HEK-293) was transfected with the pRK7-g-HRG expression vector and medium conditioned by the transfected cells was collected. The apparent molecular size of the HEK-293 expressed g-HRG was identical to that observed in medium conditioned by MDA-MB-175 cells. Although the receptor fusion protein might also detect betacellulin (Riese II et al., 1996) and other ErbB4 ligands, the agreement in the molecular size of both`natural' and recombinant argues against this possibility. Puri®cation of g-HRG from HEK-293 cell conditioned medium followed by N-terminal sequence analysis also revealed a processed form, lacking the Nterminal sequence and hydrophobic region (data not shown).
To approximate the level of secreted g-HRG in medium conditioned by MDA-MB-175 cells, binding studies were done using MCF-7 cells, which express low levels of all ErbB receptors. Displacement of [ 125 I]-rHRGb1 177 ± 244 binding with unpuri®ed conditioned medium derived from MDA-MB-175 cells was detected ( Figure 5b ). An interpolated value of *25 pM was obtained for the concentration of native g-HRG in the conditioned medium. Moreover, the ability of g-HRG to stimulate tyrosine phosphorylation of a 185 kDa protein in MCF-7 cells was also determined. Dose dependent tyrosine phosphorylation was observed after incubation with increasing concentrations of conditioned medium (Figure 5c ). Moreover in experiments not shown, lysates of MCF-7 cells treated with medium conditioned from MDA-MB-175 cells were immunoprecipitated with anti-ErbB2 or antiErbB3 speci®c antibodies. In agreement with our earlier studies (Sadick et al., 1996; Sliwkowski et al., 1994) , immunoblots of these samples probed with antiphosphotyrosine revealed a strong g-HRG-dependent increase in both ErbB2 and ErbB3 tyrosine phosphorylation.
Because N-terminal processing of g-HRG did not appear to eect receptor binding, we expressed and puri®ed an N-terminal truncated version of g-HRG as a thioredoxin (trx) fusion protein in E. coli. The puri®ed protein migrated on an SDS ± PAGE with an apparent molecular size of *60 kDa ( Figure 6a , lane 2), which is in agreement with the predicted molecular size of 64 kDa. The binding interaction of recombinant trxg-HRG with the neuregulin receptors ErbB3 or ErbB4 was performed using an in vitro system, enabling us to study binding characteristics of the individual receptors. As described elsewhere (Fitzpatrick VD, Vandlen RL and Sliwkowski MX, manuscript in preparation), IgG fusion proteins containing the extracellular domain of ErbB3 or ErbB4 were constructed and used for in vitro binding studies. Proteins in the lysate were separated by electrophoresis on a 4 ± 12% SDS-polyacrylamide gel, immunoblots were probed with anti-phosphotyrosine and developed as described in Materials and methods g-Heregulin G Schaefer et al and Sliwkowski MX, manuscript in preparation). Since the N-terminal thioredoxin sequence does not aect the binding anity of HRG (JT Jones, Genentech, Inc., personal communications) we speculate that a subpopulation of incorrectly folded proteins account for the reduced binding anity. A receptor activation assay using MCF-7 cells was performed to identify the signaling potential of E. coli expressed trxg-HRG. MCF-7 cells were treated with increasing amounts of puri®ed g-HRG and tyrosine kinase activity was determined by Western blot using an anti-phospho tyrosine antibody (Figure 6c ). trxg-HRG stimulated tyrosine phosphorylation of a 185 kDa protein on MCF-7 cells with a medium eective concentration (EC 50 ) of *60 pM, which is comparable to the value observed with rHRGb1 177 ± 244 (Sadick et al., 1996) . g-Heregulin is an autocrine growth factor for the human breast tumor cell line MDA-MB-175
ErbB2 levels in MDA-MB-175 cells are 4 ± 6 times higher than the level found in normal breast epithelial cells (Lewis et al., 1993) . Moreover, the ErbB3-ErbB2 receptor complex is constitutively tyrosine phosphorylated in MDA-MB-175 cells (Alimandi et al., 1995) . We speculated whether this activated receptor complex might be the result of g-HRG expression and might be essential for the growth of this cell line. Previously, we reported that the anti-ErbB2 monoclonal antibody 2-2C4 eectively blocks neuregulin binding and down stream signaling Lewis et al., 1996; Sliwkowski et al., 1994) . The anti-ErbB2 monoclonal antibody 2-4D5 inhibits the growth of cells that overexpress ErbB2 (Hudziak et al., 1989; Lewis et al., 1993) . Based on these characteristics, we speculated that these antibodies might be useful reagents to target cell surface receptors involved in autocrine proliferation of MDA-MB-175 cells. Additionally, the use of a soluble receptor-IgGs (Fitzpatrick VD, Vandlen RL and Sliwkowski MX, manuscript in preparation), enabled us to investigate the consequences of blocking the endogenous ligand binding to cell surface receptors. To establish that g-HRG activation of neuregulin receptors could be disrupted by 2-2C4 or ErbB4-IgG, receptor activation studies were performed with the MCF-7 cell line using medium conditioned by MDA-MB-175 cells as a source of g-HRG. As shown in Figure 7a , g-HRG activation of ErbB2 and ErbB3 is blocked when cells are treated with either 2-2C4 or ErbB4-IgG. These experiments suggested that the growth of the g-HRG-producing MDA-MB-175 cell line might also be inhibited by 2-2C4 or ErbB4-IgG. To test this possibility, MDA-MB-175 cells were treated with the anti-ErbB2 monoclonal antibodies 2-4D5, 2-2C4 (10 mg/mL) or with soluble ErbB4-IgG (10 mg/mL) for 4 days. The antiproliferative eect of antibody or soluble receptor was measured by crystal violet staining. As expected MDA-MB-175 cells (Figure 7b ) did not respond to the addition of exogenous rHRGb1 177 ± 244 since this cell line expresses and secretes g-HRG. In agreement with previous studies, incubation with 2-4D5 resulted in a moderate growth inhibition on MDA-MB-175 cells (Lewis et al., 1993) . Incubation with 2-2C4, which binds to a dierent ErbB2 epitope (Fendly et al., 1990 ) significantly inhibited (76%) cell growth in MDA-MB-175 cells by blocking the association of ErbB2 with ErbB3 . Neutralizing endogenous g-HRG with soluble ErbB4-IgG also resulted in an antiproliferative eect (63%) in MDA-MB-175 cells, which could be completely reversed by adding excess exogenous rHRGb1 177 ± 244 . SK-BR-3 cells express very high levels of ErbB2 and do not express any NRG isoforms. The lack of ligand production excludes this cell line from an autocrine growth stimulation pathway. In response to exogenous HRGb1 SK-BR-3 cells showed moderate growth stimulation. Incubation with 2-4D5 antibody had a strong inhibitory eect on cell proliferation (66%), whereas treatment with 2-2C4 antibody or ErbB4-IgG did not aect proliferation (Figure 7c ).
Discussion
In this paper we describe the molecular cloning and functional characteristics of a novel neuregulin isoform, which we have termed g-HRG. In comparison to other known neuregulins, g-HRG contains a unique Nterminal sequence, though it possesses the identical EGF-like, spacer-and Ig-like domains that are found in HRGb3. As observed with other b3-isoforms, g-HRG does not contain transmembrane or cytoplasmic domains. With the exception of GGF2 (Marchionni et al., 1993) , most neuregulins do not possess an Nterminal signal peptide and likely enter the secretory pathway through their hydrophobic transmembrane region. Proteolytic processing of pro-HRG isoforms has been demonstrated to occur both within the rough endoplasmic reticulum and at the cell surface (Burgess et al., 1995) . HRGb3, which lacks a hydrophobic domain, is not detected in the conditioned medium from transiently transfected COS-7 cells (Holmes et al., 1992; Wen et al., 1994) . In contrast, g-HRG is secreted from transiently transfected mammalian cells as well as from the native breast tumor cell line, MDA-MB-175. Secretion of g-HRG may also be due to the presence of a hydrophobic internal signal sequence, which is located in the unique N-terminal domain. A similar mechanism for secretion was postulated for the recently discovered HRG isoform, SMDF (Ho et al., 1995) . g-HRG is expressed in mesenchymal or neuronal tissues but in contrast to other HRG's it is not present in breast, lung, liver and small intestine (Holmes et al., 1992) . The transcript size is dierent than that observed in MDA-MB-175 cells suggesting that additional alternative splicing of mRNA transcripts occurs in these tissues. The lack of g-HRG transcripts in breast tissue, but its presence in the breast tumor cell line, MDA-MB-175, suggests that this isoform may have resulted from or contributed to normal breast cell transformation.
Expression of g-HRG with its cognate receptors, ErbB3 and ErbB2 suggested that the growth of the MDA-MB-175 cell line might be a result of the autocrine stimulation of a growth factor signaling pathway. The presence of autocrine loops involving coordinate growth factor and cognate receptor expression is thought to be an important paradigm in mediating neoplastic cell growth (Goustin et al., 1986; Sporn and Roberts, 1985) . Numerous receptor-ligand systems have been implicated in initiating or maintaining the transformed phenotype, increasing metastatic potential and in contributing to hormone resistance (Clarke et al., 1993; Ethier, 1995) . Despite these important biological observations, no approved, therapeutic modalities exist that are aimed at the interruption of growth factor loops in human cancer. The presence of the unique N-terminal region may serve to direct g-HRG extracellularly and allow it to interact with cell surface receptors. In contrast, other neuregulin isoforms may have limited access to receptors, since the ligands themselves may be membrane bound or attached to proteoglycan.
We have shown that neutralizing endogenous g-HRG with a soluble receptor, resulted in a substantial antiproliferative eect. At the receptor level, the mere expression of a neuregulin and ErbB3 or ErbB4 may not be sucient for a cell to maintain self-sustained Receptor activation was monitored as described in Figure 5c with an anti-phosphotyrosine immunoblot. (b) For cell proliferation studies MDA-MB-175 or (c) SK-BR-3 cells were seeded in 96 well plates and allowed to adhere for 2 h in medium containing 1% serum. Anti-ErbB2 antibodies, ErbB4-IgG (10 mg/mL each) or medium alone were added and the cells were incubated for 2 h at 378C. Subsequently rHRGb1 (1 nM), 100 nM rHRGb1 for neutralizing the ErbB4-IgG eect or medium alone were added and the cells were incubated for 4 days. Monolayers were washed and stained/®xed with 0.5% crystal violet. Absorbance was measured at 540 nm growth. Instead autocrine growth may require coexpression of either ErbB2 or EGFR. In support of this hypothesis, Zhang et al. (1996) have recently demonstrated that transformation of NIH3T3 cells by ErbB3 or ErbB4 requires the presence of either ErbB2 or EGFR. Fibroblast transformation by ErbB3 and ErbB2 is also signi®cantly enhanced by the addition of exogenous neuregulin (Wallasch et al., 1995) . Alimandi et al. (1995) reported that ErbB3 in MDA-MB-175 cells is constitutively tyrosine phosphorylated and that immunoprecipitates of ErbB3 contained high levels of PI3-kinase activity. In the present study, we extend their ®ndings, by demonstrating that MDA-MB-175 cell growth is inhibited by an antibody directed against ErbB2, which blocks the association of ErbB2 with ErbB3 and thus prevents the formation of a signaling receptor complex . Taken together, these data suggest that the activated receptor complex that is present in MDA-MB-175 cells is an ErbB3-ErbB2 complex. It is worth noting that ErbB2 levels in MDA-MB-175 cells are 3 ± 5 times higher than that found in normal breast epithelial cells (Lewis et al., 1993) and the erbB2 gene is moderately ampli®ed as determined by¯ourescent in situ hybridization (D Baly, Genentech, Inc., unpublished). It is unclear whether ErbB2 overexpression, besides g-HRG synthesis, is also a requirement for sustaining autocrine growth. This is the ®rst demonstration of a neuregulin isoform being involved in the autocrine growth of a human cell line. Autocrine growth of the rat mammary cell line, RMT was reported by Ethier et al. (1996) . Moreover, Avila et al. (1995) showed that ®broblasts transformed with the activated cph oncogene exhibit à hyperactive' autocrine loop, which is involved in the upregulation of HRG secretion with concomitant receptor activation. Two studies have also shown that stable transfection of breast cancer cells with expression vectors encoding for HRGb results in a more aggressive phenotype (Pietras et al., 1995; Tang et al., 1996) . In both of these studies, MCF7 cells, which are estrogen receptor positive and normally dependent on exogenous estrogen for growth, become hormoneindependent when engineered to express HRG. Analysis of primary breast cancer tissue has demonstrated the presence of a number of growth factors and their ligands, suggesting that autocrine systems may play a direct role in the pathobiology of tumors (Radinsky et al., 1995; Scher et al., 1995) . Our identi®cation of an active autocrine system involving neuregulin in a human breast cancer cell line warrants additional studies in epithelial-derived tumors and may provide a basis for the development of therapies directed against this growth factor-receptor pathway.
Materials and methods
Reagents
The EGF-like domain of HRGb1 177 ± 244 was expressed in E. coli, puri®ed and radioiodinated as described previously (Holmes et al., 1992; Sliwkowski et al., 1994) . The antiErbB2 monoclonal antibodies 2-2C4 and 2-4D5 have been described elsewhere (Fendly et al., 1990) . The construction and characterization of the ErbB-IgG fusion proteins will be described elsewhere (Fitzpatrick VD, Vandlen RL and Sliwkowski MX, manuscript in preparation) .
Cell culture
Human breast cancer cell lines MDA-MB-175, MDA-MB-231, SK-BR-3 and MCF-7 were obtained from the American Type Culture Collection and maintained in a 50 : 50 mixture of F12 Ham's and Dulbecco's modi®ed Eagle medium (DMEM), supplemented with 10% heat inactivated FBS, 2 mM glutamine and 10% penicillinstreptomycin.
Generation and characterization of cDNA library
Total RNA was puri®ed from MDA-MB-175 cells using the guanidinium isothiocyanate-cesium chloride procedure (Sambrook et al., 1989) . Poly (A) + RNA was isolated using oligo d(T) Dynabeads (DYNAL) as recommended by the supplier. First and second strand syntheses were performed using a Gibco BRL cDNA synthesis kit. lgt10 cDNA recombinants were generated using cDNA cloning system from Amersham. In vitro packaging was performed using Gigapack II packaging extract (Stratagene). PstI ± XhoI HRGb3 cDNA fragment (nt 635 ± 1107) was 32 P-labeled by random priming and 1610 6 plaques were screened. Positive clones were con®rmed and puri®ed by secondary and tertiary screening. Phage DNA was isolated as a BamHI fragment and subcloned into the corresponding site of pBluescript SK 7 . Clone 5 was completely sequenced using the Sequenase version 2.0 DNA sequencing kit (United States Biochemicals, Inc.). Both strands were sequenced.
Bacterial expression system
A cDNA fragment of clone 5 (nt 1690 ± 2722) was subcloned into the pET-32 TRX fusion vector (Novagen). This BgIII ± BgIII fragment was inserted into the BamHI site of the pET-32a plasmid. The trxg-HRG (amino acids 455 ± 768) protein expression in E. coli was induced as recommended by the supplier.
Puri®cation of recombinant g-HRG
E. coli cells expressing trxg-HRG were collected and suspended with 9 mL of 50 mM Tris HCl, pH 8 buer per g of cells. Lysozyme was added to a ®nal concentration of 0.2 mg/mL and the solution was stirred on ice for 1 h. DNase I (10 mg/mL) and MgCl 2 (4 mM) were added. The solution was then sonicated for 30 min and cell pellets collected afterwards. The pellet fraction was dissolved at 250 mL/g in 6 M Gdn HCl, 0.1 M Tris HCl, pH 8.8. Solubilized proteins were derivatized by adding 1/10 volume of 1 M Na 2 SO 3 and 1/10 volume of 0.2 M Na 2 S 4 O 6 . The reaction was allowed to proceed for 1.5 h at room temperature and protein was puri®ed by gel ®ltration chromatography using a High Load Superdex 1 75 prep grade column (Pharmacia). Refolding was initiated by the addition of 1 mM cysteine with 10 mM methionine added as an antioxidant and incubated overnight at room temperature. Protein concentration was determined by quantitative amino acid analysis.
Northern and Southern blot analysis
Total RNA was isolated by the method of Chomczynski and Sacchi (1987) . Poly (A) + was isolated using oligo d(T) cellulose columns (Qiagen) as recommended by the supplier. RNA was denatured and size fractionated in 0.8% formaldehyde/1% agarose gel and transferred onto nylon membrane (Hybond, Amersham). RNA was u.v. crosslinked (UV Stratalinker, Stratagene). Prehybridization was carried out at 428C in 50% formamide/1% SDS/1 M NaCl, 10% dextransulfate and 100 mg/mL herring sperm DNA for at least 2 h. cDNA probes using either a restriction fragment with complementary sequence to the EGF-like domain of HRGb3 or a KpnI ± AvaII cDNA fragment encoding the unique sequence of g-HRG (nt 1238 ± 1868) were 32 P-labeled by random priming (Prime-It II, Stratagene). Hybridization was done in identical prehybridization solutions at 428C containing the radiolabeled fragments for 16 h. Blots were washed several times with 26SSC/1% SDS at room temperature, washed again at 658C for 20 min and ®nally washed with 0.26SSC/0.1% SDS at room temperature for 15 min. The blots were air dried and exposed to Du Pont Re¯ection 1 ®lm with intensifying screens at 7808C for 7 ± 40 h. Multiple human tissue Northern Blot I and II were obtained from Clontech and hybridized with a 32 P-labeled rg-HRG probe (nt 841 ± 1447) as recommended by the supplier.
MDA-MB-175 and MDA-MB-231 genomic DNA was isolated as described in Sambrook et al. (1989) . DNA was digested with dierent restriction enzymes, treated with 0.25 N HCl and transferred onto nylon membrane (Hybond, Amersham). A BgIII ± NdeI cDNA fragment of g-HRG (nt 1690 ± 2351) was also 32 P-labeled by random priming and used as a hybridization probe. Prehybridization was carried out in 66SSC/56Denhardt's/0.75% SDS, 10% dextransulfate and 100 mg/mL herring sperm DNA at 688C for 4 h and hybridization with radiolabeled probe was done overnight. The same wash conditions for Northern blots were used as described above, except that an additional wash step was performed with 0.26SSC/0.1% SDS at 688C.
In vitro 125 I-HRG binding assay
Binding assays were performed in Nunc break-apart strip wells. Plates were coated at 48C overnight with 100 mL of 5 mg/mL goat anti human Ab (Boehringer Mannheim) in 50 mM carbonate buer (pH 9.6). Plates were rinsed twice with wash buer (PBS/0.05% Tween-20) and blocked with 100 mL 1% BSA/PBS for 30 min. Buer was removed and each well was incubated with 15 ng of receptor-IgG in 1% BSA/PBS with vigorous shaking for 1.5 h. Plates were rinsed three times with wash buer and competitive binding was carried out by adding various amounts of g-HRG and [ 125 I]-HRGb1 with vigorous shaking. After incubation for 1.5 ± 2 h, wells were rinsed three times with wash buer, drained and individual wells were counted using a 100 Series Iso Data g-counter. HRG binding assays were performed using MCF-7 cells as previously described (Lewis et al., 1996) .
Tyrosine phosphorylation assay
MCF-7 cells were plated in 24 well plates at 1610 5 cells/ well in F12/DMEM containing 10% FBS. After 48 h, cells were washed with serum free F12/DMEM and serum starved for 6 h. Various concentrations of bacterially expressed truncated g-HRG or unpuri®ed conditioned medium of MDA-MB-175 cells were prepared in binding buer (0.1% BSA in F12/DMEM) and added to each well.
After incubation for 8 min at room temperature, media was carefully aspirated and reactions were stopped by adding 100 mL of sample buer (5% SDS, 0.25% 2-mercaptoethanol, 25 mM Tris-HCl pH 6.8). Each sample (20 mL) was subjected to SDS ± PAGE using a 4 ± 12% gradient gel (Novex) and then electrophoretically transferred onto nitrocellulose membrane. Anti-phosphotyrosine (4G10, from UBI, used at 1 mg/mL) immunoblots were developed with ECL Western blotting reagents (Amersham) and the predominant reactive band at M r *180 kDa was quanti®ed by re¯ectance densitometry.
Cell proliferation assay with crystal violet
Tumor cell lines were plated in 96 well plates at following densities: 2610 4 cells/well for MDA-MB-175 and 1610 4 cells/well for SK-BR-3. The media contained 1% FBS and cells were allowed to adhere for 2 h. Monoclonal antibodies, receptor-IgGs (10 mg/mL) or media alone were added and the cells were incubated for 2 h at 378C. rHRGb1 177 ± 244 was added at a ®nal concentration of either 1 nM or 100 nM to neutralize the receptor-IgG, and the cells were incubated for 4 days. Monolayers were washed with PBS and stained/®xed with 0.5% crystal violet. Plates were air dried, the dye was eluted with 0.1 M sodium citrate (pH 4.2) in ethanol (50 : 50) and the absorbance was measured at 540 nm.
Nucleotide sequence accession number
The GenBank nucleotide sequence accession number for the reported sequence is AFOOg227.
Note added in proof
In this paper, we use the term neuregulin to denote the entire family of isoforms that are ligands for ErbB3 and ErbB4. The term heregulin, HRG, will be used for neuregulin family members that contain immunoglobulinlike, spacer and EGF-like domains. In this context, HRGs are the human homologues of the rodent proteins neu dierentiation factors, NDFs. We designate the new HRG isoform described in this paper as g-HRG, since it is the third major class of HRGs to be identi®ed from a breast cancer cell.
